The study proposed is the first meta-analysis aimed at assessing the long-term overall survival, major molecular response (MMR) and cytogenetic response (CCyR) of second-generation BCR-ABL TKIs compared with imatinib in patients with CML in RCTs. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.